Basic information Safety Supplier Related

NVP-LCQ195

Basic information Safety Supplier Related

NVP-LCQ195 Basic information

Product Name:
NVP-LCQ195
Synonyms:
  • 4-(2,6-Dichlorobenzamido)-N-(1-(methylsulfonyl)piperidin-4-yl)-1H-pyrazole-3-carboxamide
  • NVP-LCQ195;LCQ-195;AT-9311;NVP LCQ195
  • NVP-LCQ195
  • AT 9311
  • AT-9311
  • LCQ 195
  • LCQ-195
  • 4-(2,6-Dichlorobenzoylamino)-1H-pyrazole-3-carboxylic acid N-[1-(methylsulfonyl)piperidin-4-yl]amide
CAS:
902156-99-4
MF:
C17H19Cl2N5O4S
MW:
460.33486
Mol File:
902156-99-4.mol
More
Less

NVP-LCQ195 Chemical Properties

Density 
1.57±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
insoluble in H2O; ≥152.4 mg/mL in DMSO; ≥3.28 mg/mL in EtOH with gentle warming and ultrasonic
form 
solid
pka
11.10±0.70(Predicted)
color 
White to off-white
More
Less

NVP-LCQ195 Usage And Synthesis

Uses

NVP-LCQ195 (AT9311; LCQ195) is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM. IC50 Value: 1 nM(CDK5/p25 and CDK5/p35); 2 nM(CDK1/cyclinB and CDK2/cyclinA); 5 nM(CDK2/cyclinE); 42 nM(CDK3/cyclinE) Target: CDKs LCQ195 induced cell cycle arrest and eventual apoptotic cell death of MM cells, even at sub-lmol/l concentrations, spared non-malignant cells, and overcame the protection conferred to MM cells by stroma or cytokines of the bone marrow milieu. In MM cells, LCQ195 triggered decreased amplitude of transcriptional signatures associated with oncogenesis, drug resistance and stem cell renewal, including signatures of activation of key transcription factors for MM cells e.g. myc, HIF-1a, IRF4. Bortezomib-treated MM patients whose tumours had high baseline expression of genes suppressed by LCQ195 had significantly shorter progression-free and overall survival than those with low levels of these transcripts in their MM cells. These observations provide insight into the biological relevance of multi-targeted CDK inhibition in MM.

IC 50

Cdk5/p25: 1 nM (IC50); CDK5/p35: 1 nM (IC50); Cdk1/cyclin B: 2 nM (IC50); cdk2/cyclin A: 2 nM (IC50); CDK2/cyclinE: 5 nM (IC50); CDK9/cyclinT1: 15 nM (IC50); CDK3/Cyclin E: 42 nM (IC50); cdk6/cyclin D3: 187 nM (IC50); CDK7/Cyclin H/MAT1: 3564 nM (IC50)

References

[1] McMillin DW, Delmore J, Negri J et al. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb;152(4):420-32. DOI:10.1111/j.1365-2141.2010.08427.x

NVP-LCQ195Supplier

Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
MedChemexpress LLC
Tel
021-58955995
Email
sales@medchemexpress.cn
ShangHai KenEn Chemical Technology Co., Ltd.
Tel
13120367189
Email
mychess007@163.com